Biomedical
Peer Reviewed
Doi: http://dx.doi.org/10.1186/s13053-024-00281-9
Current National Comprehensive Cancer Network ® (NCCN ®) guidelines for Colorectal Genetic/Familial High-Risk Assessment provide limited guidance for genetic testing for individuals with already diagnosed hereditary cancer conditions. We are presenting the case of a 36-year-old woman who was diagnosed with Lynch Syndrome at age 23 after genetic testing for a familial variant (c.283del) in the MLH1 gene. The patient had a previous history of Hodgkin Lymphoma at the time of familial variant testing, and she would later develop stage IIIa cecal adenocarcinoma at age 33 and metastatic papillary thyroid carcinoma at age 35. The patient’s family history included a first-degree relative who was diagnosed with colorectal cancer at age 39, multiple second-degree relatives with colorectal, endometrial, and stomach cancer, and third and fourth-degree relatives with breast cancer. In light of her personal and family history, a comprehensive cancer panel was recommended. This panel found a second hereditary cancer predisposition syndrome: a likely pathogenic variant (c. 349 A G) in the CHEK2 gene. This specific CHEK2 variant was recently reported to confer a moderately increased risk for breast cancer. The discovery of this second cancer predisposition syndrome had important implications for the patient’s screening and risk management. While uncommon, the possibility of an individual having multiple cancer predisposition syndromes is important to consider when evaluating patients and families for hereditary cancer, even when a familial variant has been identified.
Recognizing multiple hereditary cancer syndromes in a patient is crucial as it can influence cancer risk assessment, screening protocols, and personalized management strategies, ensuring comprehensive care.
The discovery of a likely pathogenic CHEK2 variant, in addition to her known MLH1 mutation, led to adjustments in her cancer screening and prevention strategies, tailored to address the risks associated with both genetic mutations.
Comprehensive genetic testing can uncover additional pathogenic variants that may not be explained by a single familial mutation, providing a more complete understanding of a patient's cancer risk and informing more effective management plans.
This case suggests that current guidelines may need to be updated to recommend broader genetic testing for individuals with personal or family histories suggestive of multiple hereditary cancer syndromes, even if a known familial variant has been identified.
Show by month | Manuscript | Video Summary |
---|---|---|
2025 April | 1 | 1 |
2025 March | 49 | 49 |
2025 February | 50 | 50 |
2025 January | 48 | 48 |
2024 December | 42 | 42 |
2024 November | 53 | 53 |
2024 October | 32 | 32 |
Total | 275 | 275 |
Show by month | Manuscript | Video Summary |
---|---|---|
2025 April | 1 | 1 |
2025 March | 49 | 49 |
2025 February | 50 | 50 |
2025 January | 48 | 48 |
2024 December | 42 | 42 |
2024 November | 53 | 53 |
2024 October | 32 | 32 |
Total | 275 | 275 |
Doi: http://dx.doi.org/10.1186/s13053-024-00281-9